We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+25.23%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.35B
AUM Growth
+$326M
Cap. Flow
+$191M
Cap. Flow %
14.16%
Top 10 Hldgs %
71.47%
Holding
42
New
4
Increased
13
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
LAB icon
Standard BioTools
LAB
+$147M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27.2M
3
VCYT icon
Veracyte
VCYT
+$20.9M
4
EXAS
Exact Sciences
EXAS
+$14.5M
5
RNAM
Avidity Biosciences
RNAM
+$14.2M

Top Sells

Rank Stock Value
1
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$31.9M
2
PLRX icon
Pliant Therapeutics
PLRX
+$9.52M
3
ILMN icon
Illumina
ILMN
+$8.96M
4
FATE icon
Fate Therapeutics
FATE
+$7.67M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$5.97M

Sector Composition

Rank Sector Weight
1 Healthcare 99.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDXS icon
26
Codexis
CDXS
$156M
$6.98M 0.52%
2,000,000
– –
ABSI icon
27
Absci
ABSI
$1.35B
$5.53M 0.41%
973,260
– –
PACB icon
28
Pacific Biosciences
PACB
$441M
$3.88M 0.29%
1,035,859
– –
KYTX icon
29
Kyverna Therapeutics
KYTX
$457M
$3.73M 0.28%
+150,000
New +$4.19M
GLUE icon
30
Monte Rosa Therapeutics
GLUE
$1.3B
$3.6M 0.27%
510,882
– –
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.7B
$3.57M 0.27%
150,000
– –
PRME icon
32
Prime Medicine
PRME
$508M
$2.57M 0.19%
367,175
– –
DNA icon
33
Ginkgo Bioworks
DNA
$584M
$1.69M 0.13%
+36,494
New +$1.89M
NTLA icon
34
CALL
Intellia Therapeutics
NTLA
$1.5B
$1.38M 0.1%
+50,000
New +$1.39M
EXAI
35
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$1.22M 0.09%
213,900
– –
OMIC
36
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$681K 0.05%
44,130
– –
KRON
37
DELISTED
Kronos Bio
KRON
$161K 0.01%
123,839
– –
FATE icon
38
Fate Therapeutics
FATE
$291M
– –
-2,050,000
Closed -$7.67M
GPCR icon
39
CALL
Structure Therapeutics
GPCR
$3.44B
– –
-25,000
Closed -$1.02M
ILMN icon
40
CALL
Illumina
ILMN
$30B
– –
-25,700
Closed -$3.48M
LIAN
41
DELISTED
LianBio American Depositary Shares
LIAN
– –
-206,415
Closed -$923K
SLGC
42
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-12,604,275
Closed -$31.9M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Casdin Capital held 42 positions worth $1.35B, up 32% from $1.02B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Casdin Capital deployed $191M of net new capital in Q1 2024, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Veracyte: 857,904 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Pliant Therapeutics, an estimated $9.52M trimmed.

  • Casdin Capital's largest Q1 2024 buy was Veracyte: 857,904 shares worth $19M.
  • Casdin Capital added most to Standard BioTools in Q1 2024, an estimated $147M increase.
  • Casdin Capital's biggest Q1 2024 reduction was Pliant Therapeutics, cutting an estimated $9.52M.
  • Casdin Capital fully exited SomaLogic, Inc. Class A Common Stock in Q1 2024, selling an estimated $31.9M.
  • Casdin Capital's ten largest holdings make up 71% of its $1.35B portfolio in Q1 2024.
  • Casdin Capital opened 4 new positions and closed 5 in Q1 2024.
  • Casdin Capital's portfolio value rose 32% quarter-over-quarter to $1.35B.

Based on Casdin Capital's 13F filing for Q1 2024, filed 15 May 2024.